NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00069-0153-02 | 00069-0153 | Cytarabine | Cytarabine | 20.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Dec 14, 2011 | Jun 30, 2014 | No Longer Used |
25021-0222-04 | 25021-0222 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 1, 2013 | Mar 31, 2017 | No Longer Used |
25021-0222-01 | 25021-0222 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jul 1, 2013 | Mar 31, 2017 | No Longer Used |
43598-0611-11 | 43598-0611 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 22, 2017 | In Use | |
00409-5068-01 | 00409-5068 | DOCETAXEL | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Jun 28, 2021 | In Use | |
44087-3535-01 | 44087-3535 | Avelumab | Bavencio | 20.0 mg/mL | Immunotherapy | Checkpoint Inhibitor | PD-L1 | Intravenous | Mar 23, 2017 | In Use | |
16714-0726-01 | 16714-0726 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jun 15, 2017 | Apr 30, 2020 | In Use |
68001-0426-22 | 68001-0426 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jul 7, 2020 | Aug 11, 2021 | No Longer Used |
63323-0193-55 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 1, 2009 | In Use | |
63323-0193-02 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Apr 1, 2009 | In Use | |
45963-0614-55 | 45963-0614 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Mar 12, 2015 | In Use | |
55150-0352-01 | 55150-0352 | IRINOTECAN HYDROCHLORIDE | IRINOTECAN HYDROCHLORIDE | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb 11, 2020 | In Use | |
68001-0265-23 | 68001-0265 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Nov 14, 2013 | In Use | |
47335-0323-40 | 47335-0323 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov 26, 2020 | In Use | |
83513-0010-01 | 83513-0010 | Docetaxel | BEIZRAY | 20.0 mg/ml | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 23, 2024 | In Use | |
64067-0216-01 | 64067-0216 | Methoxsalen | UVADEX | 20.0 ug/mL | Chemotherapy | Photosensitizing Agent | Psoralen | Extracorporeal | Feb 25, 1999 | In Use | |
00378-1201-78 | 00378-1201 | Sorafenib | Sorafenib Tosylate | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF | Oral | Jun 1, 2022 | In Use | |
80739-0812-12 | 80739-0812 | Adagrasib | KRAZATI | 200.0 mg/1 | Immunotherapy | RAS Inhibitor | KRAS G12C | Oral | Dec 12, 2022 | In Use | |
00310-9501-01 | 00310-9501 | Capivasertib | TRUQAP | 200.0 mg/1 | Chemotherapy | AKT Inhibitor | AKT1/2/3 | Oral | Nov 16, 2023 | In Use | |
50419-0489-01 | 50419-0489 | Sorafenib | Nexavar | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, PDGFR, KIT, RET, RET/PTC, FLT3, CRAF, BRAF | Oral | Oct 2, 2023 | In Use | |
43826-0066-04 | 43826-0066 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Dec 1, 2022 | In Use | |
79802-0200-30 | 79802-0200 | belumosudil | Rezurock | 200.0 mg/1 | Chemotherapy | Rho Kinase Inhibitor | ROCK 1, ROCK2 | Oral | Jul 16, 2021 | In Use | |
13668-0682-30 | 13668-0682 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR, KIT, RET, RET/PTC, CRAF, BRAF | Oral | Apr 12, 2023 | In Use | |
43598-0458-36 | 43598-0458 | Sorafenib | Sorafenib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, KIT, RET, CRAF, BRAF | Oral | Jun 8, 2022 | In Use | |
59572-0220-16 | 59572-0220 | Thalidomide | Thalomid | 200.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Jun 20, 2003 | In Use |
Found 11765 results — Export these results